Yrondi, Antoine

Les professionnels de santé face à la pandémie de la maladie à coronavirus (COVID-19) : quels risques pour leur santé mentale ?

El-Hage, W., Hingray, C., Lemogne, C., Yrondi, A., Brunault, P., Bienvenu, T., Etain, B., Paquet, C., Gohier, B., Bennabi, D., et al. (2020) · L'Encéphale

COVID-19 and Mental HealthHealthcare professionals’ stress and burnout

Cited by 457

Childhood maltreatment and clinical severity of treatment‐resistant depression in a French cohort of outpatients (FACE‐DR): One‐year follow‐up

Yrondi, A., Aouizerate, B., Bennabi, D., Richieri, R., D'Amato, T., Bellivier, F., Bougerol, T., Horn, M., Camus, V., Courtet, P., et al. (2020) · Depression and Anxiety

Child Abuse and TraumaTreatment of Major Depression

Cited by 37

Assessment of Translocator Protein Density, as Marker of Neuroinflammation, in Major Depressive Disorder: A Pilot, Multicenter, Comparative, Controlled, Brain PET Study (INFLADEP Study)

Yrondi, A., Aouizerate, B., El-Hage, W., Moliere, F., Thalamas, C., Delcourt, N., Sporer, M., Taib, S., Schmitt, L., Arlicot, N., et al. (2018) · Frontiers in Psychiatry

Tryptophan and brain disordersTreatment of Major Depression

Cited by 19

Withdrawal syndrome after antipsychotics discontinuation: an analysis of the WHO database of spontaneous reports (Vigibase) between 2000 and 2022

Storck, W., de Laportalière, T. T., Yrondi, A., Javelot, H., Berna, F., & Montastruc, F. (2024) · Psychopharmacology

Schizophrenia research and treatmentPharmacovigilance and Adverse Drug Reactions

Cited by 10

Association between major cardiovascular events and esketamine: A disproportionality analysis in the WHO pharmacovigilance database

Taillefer de Laportalière, T., Horowitz, M. A., Soeiro, T., Lepetit, M., Jullien, A., Yrondi, A., Moncrieff, J., Naudet, F., & Montastruc, F. (2025) · European Neuropsychopharmacology

Pharmacovigilance and Adverse Drug ReactionsTreatment of Major Depression

Cited by 2